disufenton sodium has been researched along with Infarction, Middle Cerebral Artery in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Balogh, GT; Fischer, J; Gere, A; Kis-Varga, A; Könczöl, A; Vukics, K | 1 |
| Bowes, LJ; Cummings, RM; Green, AR; Marshall, JW; Ridley, RM | 1 |
| Hess, DC | 1 |
| Hori, O; Izuhara, Y; Kitao, Y; Miyata, T; Morita, Y; Ogawa, S; Takagi, S; Takizawa, S; van Ypersele de Strihou, C | 1 |
| Duffin, KJ; Green, AR; Marshall, JW; Ridley, RM | 1 |
| Borelli, AR; Cross, AJ; Green, AR; Sydserff, SG | 1 |
6 other study(ies) available for disufenton sodium and Infarction, Middle Cerebral Artery
| Article | Year |
|---|---|
Nitrone derivatives of trolox as neuroprotective agents.
Topics: Animals; Antioxidants; Arterial Occlusive Diseases; Brain Ischemia; Cerebrovascular Circulation; Chromans; Free Radical Scavengers; Hydroxyl Radical; Infarction, Middle Cerebral Artery; Lipid Peroxidation; Mice; Neuroprotective Agents; Nitrogen Oxides; Structure-Activity Relationship | 2005 |
Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion.
Topics: Animals; Benzenesulfonates; Callithrix; Disease Models, Animal; Drug Evaluation, Preclinical; Infarction, Middle Cerebral Artery; Motor Activity; Neuroprotective Agents; Nitrogen Oxides; Perceptual Disorders; Recovery of Function; Stroke; Time Factors; Treatment Outcome | 2003 |
NXY-059: a hopeful sign in the treatment of stroke.
Topics: Animals; Benzenesulfonates; Callithrix; Chlormethiazole; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Evaluation, Preclinical; Excitatory Amino Acid Antagonists; Fibrinolytic Agents; Free Radical Scavengers; Hemorrhage; Humans; Infarction, Middle Cerebral Artery; Neuroprotective Agents; Nitrogen Oxides; Pyridines; Randomized Controlled Trials as Topic; Research Design; Rodentia; Stroke; Thrombolytic Therapy; Tissue Plasminogen Activator; Treatment Outcome | 2006 |
A novel inhibitor of advanced glycation and endoplasmic reticulum stress reduces infarct volume in rat focal cerebral ischemia.
Topics: Animals; Antioxidants; Antipyrine; Benzenesulfonates; Blood Pressure; Brain Ischemia; Cell Death; Dose-Response Relationship, Drug; Edaravone; Endoplasmic Reticulum; Furans; Glycation End Products, Advanced; Immunohistochemistry; Indicators and Reagents; Infarction, Middle Cerebral Artery; Intracranial Thrombosis; Male; Mice; Mice, Knockout; Neuroprotective Agents; Oxidation-Reduction; Oxidative Stress; Protein Denaturation; Pyridines; Rats; Rats, Sprague-Dawley | 2007 |
NXY-059, a free radical--trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species.
Topics: Analysis of Variance; Animals; Arm; Behavior, Animal; Benzenesulfonates; Body Temperature; Brain; Brain Ischemia; Callithrix; Choice Behavior; Disease Models, Animal; Free Radical Scavengers; Hemodynamics; Infarction, Middle Cerebral Artery; Infusions, Intravenous; Kinesis; Motor Activity; Neuroprotective Agents; Nitrogen Oxides; Paresis; Perceptual Disorders | 2001 |
Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window.
Topics: Administration, Cutaneous; Animals; Benzenesulfonates; Brain Ischemia; Cerebral Cortex; Cerebral Infarction; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Infarction, Middle Cerebral Artery; Infusion Pumps, Implantable; Ischemic Attack, Transient; Male; Neuroprotective Agents; Nitrogen Oxides; Rats; Rats, Inbred WKY | 2002 |